ResMed Bull Stays Positive on Margin, Earnings -- Market Talk

Dow Jones

06/03

0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 03, 2025 02:51 ET (06:51 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540747982"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540747982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540747982?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 14:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540747982","market":"hk","top_or_hot":-1,"title":"ResMed Bull Stays Positive on Margin, Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 02:51 ET (06:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Bull Stays Positive on Margin, Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Bull Stays Positive on Margin, Earnings -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-06-03 14:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 02:51 ET (06:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD.AU","symbol_name":"Resmed DRC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540747982","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540747982","pubTimestamp":1748933460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RMD.AU":"Resmed DRC","RMD":"瑞思迈"},"translate_title":"瑞思迈牛市对利润率和盈利保持乐观——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2025 02:51 ET (06:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}